一线拉米夫定/多替拉韦在HIV感染者中的真实世界疗效:ICONA队列数据
该研究基于ICONA队列2016至2024年启动一线拉米夫定/多替拉韦的446例HIV感染者,中位随访22个月,3年治疗失败累积概率为5.8%(95%CI:2.9%-8.7%),低于随机试验。
要点
- 真实世界中一线拉米夫定/多替拉韦3年治疗失败率低于6%,优于随机试验数据。
- 3年治疗中断概率为13.4%,纯病毒学失败概率仅2.3%。
核心结论
- 真实世界一线拉米夫定/多替拉韦3年治疗失败概率低于6%,低于随机试验报告。
研究设计与样本
- 基于ICONA队列的观察性研究,纳入2016至2024年启动一线拉米夫定/多替拉韦的446例HIV感染者。
- 主要终点为治疗失败时间,定义为病毒学失败或因毒性/缺乏病毒学控制/不依从停药或任何原因死亡。
- 采用标准生存分析和Cox回归模型,中位随访22个月。
主要发现
- 446例中4.3%(n=19)发生治疗失败,3年累积概率为5.8%(95%CI:2.9%-8.7%)。
- 基线CD4计数与治疗失败风险升高3倍相关,校正后风险降低。
- 出生性别与治疗失败风险无差异。
- 3年治疗中断和病毒学失败概率分别为13.4%(95%CI:9.1%-17.6%)和2.3%(95%CI:0.19%-4.4%)。
临床怎么用
- 一线拉米夫定/多替拉韦在真实世界中疗效良好,3年治疗失败率低。
局限性
- 需更大规模研究来确证各风险因素效应的大小。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: This analysis aimed to evaluate the rate of failure of first-line lamivudine/dolutegravir in a real-world setting and assess the effectiveness among people with HIV (PWH) at higher risk of suboptimal response. METHODS: The study included PWH from the ICONA cohort who started first-line lamivudine/dolutegravir between 2016 and 2024. The primary endpoint was time to treatment failure (TF), defined as virological failure (VF, two consecutive HIV-RNA of >50 copies/mL >6 months after treatment initiation) or discontinuation due to toxicity/lack virological control/non-adherence or death for any cause. Secondary endpoints were time to treatment discontinuation for any reason (TD) and pure VF. Main exposures of interest were baseline CD4 and HIV-RNA, age, sex at birth and nation of birth. Standard survival analysis and Cox regression models were used. RESULTS: Among 446 participants, after a median follow-up of 22 months, 4.3% (n = 19) experienced TF, the 3 year cumulative probability was 5.8% (95% CI: 2.9%-8.7%). Baseline CD4 count was associated with a 3-fold higher risk of TF, which decreased after adjustments. Higher viral loads (>100 000 copies/mL), age >50 years and foreign-born status were also associated with an increased risk of TF. No differences in TF according to sex at birth were found. By 3 years the probabilities of TD and VF were 13.4% (95% CI: 9.1%-17.6%) and 2.3% (95% CI: 0.19%-4.4%), respectively. CONCLUSIONS: In our real-world setting, the TF probability for first-line lamivudine/dolutegravir was below 6% at 3 years, lower than in randomized trials. Our data suggest that, as shown with other regimens, PWH starting lamivudine/dolutegravir with CD4 count of ≤200 cells/mm3, HIV-RNA of >100 000 copies/mL, older age or foreign-born status may be at higher risk of TF, though larger studies are needed to qualify the magnitude of the effect.
引用
- Vergori A, Cozzi-Lepri A, Lo Caputo S, et al. Effectiveness of first-line lamivudine/dolutegravir antiretroviral therapy in persons with HIV: real-life data from the ICONA Foundation cohort. J Antimicrob Chemother. 2025. PMID: 40985146. doi:10.1093/jac/dkaf345
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。